• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HMGA2 对于胰腺癌的发生、转移和治疗抵抗是可有可无的。

Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance.

机构信息

Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

出版信息

Sci Rep. 2018 Sep 18;8(1):14008. doi: 10.1038/s41598-018-32159-x.

DOI:10.1038/s41598-018-32159-x
PMID:30228296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6143627/
Abstract

Expression of the chromatin-associated protein HMGA2 correlates with progression, metastasis and therapy resistance in pancreatic ductal adenocarcinoma (PDAC). Hmga2 has also been identified as a marker of a transient subpopulation of PDAC cells that has increased metastatic ability. Here, we characterize the requirement for Hmga2 during growth, dissemination, and metastasis of PDAC in vivo using conditional inactivation of Hmga2 in well-established autochthonous mouse models of PDAC. Overall survival, primary tumour burden, presence of disseminated tumour cells in the peritoneal cavity or circulating tumour cells in the blood, and presence and number of metastases were not significantly different between mice with Hmga2-wildtype or Hmga2-deficient tumours. Treatment of mice with Hmga2-wildtype and Hmga2-deficient tumours with gemcitabine did not uncover a significant impact of Hmga2-deficiency on gemcitabine sensitivity. Hmga1 and Hmga2 overlap in their expression in both human and murine PDAC, however knockdown of Hmga1 in Hmga2-deficient cancer cells also did not decrease metastatic ability. Thus, Hmga2 remains a prognostic marker which identifies a metastatic cancer cell state in primary PDAC, however Hmga2 has limited if any direct functional impact on PDAC progression and therapy resistance.

摘要

染色质相关蛋白 HMGA2 的表达与胰腺导管腺癌 (PDAC) 的进展、转移和治疗耐药性相关。Hmga2 也被确定为 PDAC 细胞短暂亚群的标志物,该亚群具有增加的转移能力。在这里,我们使用在已建立的 PDAC 自发模型中条件性失活 Hmga2 来表征 HMGA2 在 PDAC 体内生长、扩散和转移中的需求。在 Hmga2 野生型或 Hmga2 缺失型肿瘤小鼠中,总体存活率、原发性肿瘤负担、腹腔内播散性肿瘤细胞的存在或血液中循环肿瘤细胞的存在以及转移的存在和数量均无显著差异。用吉西他滨治疗 Hmga2 野生型和 Hmga2 缺失型肿瘤的小鼠并未发现 Hmga2 缺失对吉西他滨敏感性有显著影响。Hmga1 和 Hmga2 在人类和鼠 PDAC 中的表达存在重叠,但在 Hmga2 缺失型癌细胞中敲低 Hmga1 也不会降低转移能力。因此,HMGA2 仍然是一个预后标志物,它在原发性 PDAC 中识别出一种转移性癌细胞状态,但 Hmga2 对 PDAC 进展和治疗耐药性的直接功能影响有限,如果有的话。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5691/6143627/7c2343b836b2/41598_2018_32159_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5691/6143627/90e2f0077bce/41598_2018_32159_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5691/6143627/5aa73c12ae15/41598_2018_32159_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5691/6143627/36ba0748dbd1/41598_2018_32159_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5691/6143627/7c2343b836b2/41598_2018_32159_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5691/6143627/90e2f0077bce/41598_2018_32159_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5691/6143627/5aa73c12ae15/41598_2018_32159_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5691/6143627/36ba0748dbd1/41598_2018_32159_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5691/6143627/7c2343b836b2/41598_2018_32159_Fig4_HTML.jpg

相似文献

1
Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance.HMGA2 对于胰腺癌的发生、转移和治疗抵抗是可有可无的。
Sci Rep. 2018 Sep 18;8(1):14008. doi: 10.1038/s41598-018-32159-x.
2
Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.三维胶原 I 通过 MT1-MMP 介导的 HMGA2 表达促进胰腺癌对吉西他滨的耐药性。
Cancer Res. 2011 Feb 1;71(3):1019-28. doi: 10.1158/0008-5472.CAN-10-1855. Epub 2010 Dec 8.
3
CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.CIP2A的下调增强了胰腺癌细胞对吉西他滨的敏感性。
Oncotarget. 2016 Mar 22;7(12):14831-40. doi: 10.18632/oncotarget.7447.
4
S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.S100A14 促进胰腺癌的进展和吉西他滨耐药性。
Pancreatology. 2021 Apr;21(3):589-598. doi: 10.1016/j.pan.2021.01.011. Epub 2021 Jan 22.
5
Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.CD36 对胰腺导管腺癌化疗耐药性的影响。
Ann Surg Oncol. 2020 Feb;27(2):610-619. doi: 10.1245/s10434-019-07927-2. Epub 2019 Oct 11.
6
Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC.基质调节的HMGA2是胰腺导管腺癌和阑尾腺癌中的一个独立预后标志物。
Br J Cancer. 2017 Jun 27;117(1):65-77. doi: 10.1038/bjc.2017.140. Epub 2017 May 18.
7
Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.抑制信号转导子和转录激活子 3 可增加吉西他滨的反应,并延缓胰腺癌的进展。
Mol Cancer. 2013 Sep 11;12(1):104. doi: 10.1186/1476-4598-12-104.
8
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.上皮-间质转化对胰腺癌转移并非必需,但可诱导其产生化疗耐药性。
Nature. 2015 Nov 26;527(7579):525-530. doi: 10.1038/nature16064. Epub 2015 Nov 11.
9
HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma.HMGA1 和 HMGA2 蛋白表达与胰腺腺癌的高级别肿瘤分级和淋巴结转移相关。
Histopathology. 2012 Feb;60(3):397-404. doi: 10.1111/j.1365-2559.2011.04121.x.
10
Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.骨膜蛋白促进胰腺癌对吉西他滨的化疗耐药性。
Tumour Biol. 2016 Nov;37(11):15283-15291. doi: 10.1007/s13277-016-5321-6. Epub 2016 Sep 30.

引用本文的文献

1
Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research.新发糖尿病与胰腺癌研究的当前范式及未来展望
Front Pharmacol. 2025 May 23;16:1543112. doi: 10.3389/fphar.2025.1543112. eCollection 2025.
2
HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity.HMGA2与蛋白质亮氨酸甲基化驱动胰腺癌谱系可塑性。
Nat Commun. 2025 May 26;16(1):4866. doi: 10.1038/s41467-025-60129-1.
3
HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma.

本文引用的文献

1
High Mobility Group A (HMGA) proteins: Molecular instigators of breast cancer onset and progression.高迁移率族 A(HMGA)蛋白:乳腺癌发生和发展的分子启动子。
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):216-229. doi: 10.1016/j.bbcan.2018.03.001. Epub 2018 Mar 6.
2
Cancer statistics, 2018.癌症统计数据,2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
3
CXCR4/Let-7a Axis Regulates Metastasis and Chemoresistance of Pancreatic Cancer Cells Through Targeting HMGA2.CXCR4/Let-7a轴通过靶向HMGA2调控胰腺癌细胞的转移和化疗耐药性。
HMGA2表达可预测胰腺导管腺癌的亚型、生存率及治疗结果。
Clin Cancer Res. 2025 Feb 17;31(4):733-745. doi: 10.1158/1078-0432.CCR-24-2200.
4
Decoding high mobility group A2 protein expression regulation and implications in human cancers.解读高迁移率族蛋白A2的表达调控及其在人类癌症中的意义
Discov Oncol. 2024 Jul 31;15(1):322. doi: 10.1007/s12672-024-01202-x.
5
HMGA2 overexpression activates IGF2BP2 to stabilize APLP2 via m6A modification and promote pancreatic cancer progression.HMGA2过表达通过m6A修饰激活IGF2BP2以稳定APLP2并促进胰腺癌进展。
Heliyon. 2024 Feb 28;10(5):e27268. doi: 10.1016/j.heliyon.2024.e27268. eCollection 2024 Mar 15.
6
CircTHSD4 promotes the malignancy and docetaxel (DTX) resistance in prostate cancer by regulating miR-203/HMGA2 axis.环状 THSD4 通过调控 miR-203/HMGA2 轴促进前列腺癌的恶性转化和多西他赛(DTX)耐药性。
Oncol Res. 2024 Feb 6;32(3):529-544. doi: 10.32604/or.2023.031511. eCollection 2024.
7
Epigenetic reprogramming-induced guanidinoacetic acid synthesis promotes pancreatic cancer metastasis and transcription-activating histone modifications.表观遗传重编程诱导胍基乙酸合成促进胰腺癌转移和转录激活组蛋白修饰。
J Exp Clin Cancer Res. 2023 Jun 28;42(1):155. doi: 10.1186/s13046-023-02698-x.
8
microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer.胰腺癌中通过上皮-间质转化、肿瘤微环境和药物代谢与吉西他滨耐药相关的微小RNA
Cancers (Basel). 2023 Feb 15;15(4):1230. doi: 10.3390/cancers15041230.
9
Evaluation of Serum microRNA Let-7c and Let-7d as Predictive Biomarkers for Metastatic Pancreatic Cancer.血清 microRNA Let-7c 和 Let-7d 作为转移性胰腺癌预测性生物标志物的评估。
Turk J Gastroenterol. 2022 Aug;33(8):696-703. doi: 10.5152/tjg.2022.21829.
10
The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer.放化疗联合补体 C3a 抑制增强自然杀伤细胞对胰腺癌的作用。
Cancer Res Commun. 2022 Jul;2(7):725-738. doi: 10.1158/2767-9764.crc-22-0069. Epub 2022 Jul 27.
Cell Physiol Biochem. 2017;43(2):840-851. doi: 10.1159/000481610. Epub 2017 Sep 28.
4
BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer.BLIMP1 诱导胰腺癌中的转移性异质性瞬时变化。
Cancer Discov. 2017 Oct;7(10):1184-1199. doi: 10.1158/2159-8290.CD-17-0250. Epub 2017 Aug 8.
5
Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis.胰腺癌进展过程中的表观基因组重编程将合成代谢性葡萄糖代谢与远处转移联系起来。
Nat Genet. 2017 Mar;49(3):367-376. doi: 10.1038/ng.3753. Epub 2017 Jan 16.
6
Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer.胰腺癌个体患者转移灶中已知驱动基因突变的异质性有限。
Nat Genet. 2017 Mar;49(3):358-366. doi: 10.1038/ng.3764. Epub 2017 Jan 16.
7
An in vivo multiplexed small-molecule screening platform.一种体内多重小分子筛选平台。
Nat Methods. 2016 Oct;13(10):883-889. doi: 10.1038/nmeth.3992. Epub 2016 Sep 12.
8
Pancreatic cancer.胰腺癌。
Nat Rev Dis Primers. 2016 Apr 21;2:16022. doi: 10.1038/nrdp.2016.22.
9
Hmga2 is dispensable for cutaneous squamous cell carcinoma.Hmga2对皮肤鳞状细胞癌并非必需。
Exp Dermatol. 2016 May;25(5):409-12. doi: 10.1111/exd.12978.
10
Genetics and biology of pancreatic ductal adenocarcinoma.胰腺导管腺癌的遗传学与生物学
Genes Dev. 2016 Feb 15;30(4):355-85. doi: 10.1101/gad.275776.115.